CF Organization of Care in the Era of Highly Effective Modulator.
- Sponsor
- Hospices Civils de Lyon
- Study ID
- NCT06599892
- Status
- Recruiting
Conditions
- Cystic Fibrosis
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intervention mapping — OTHERIntervention mapping is a model combining patient and professional questionnaires and a qualitative survey using individual interviews with patients and focus groups with professionals to identify the obstacles and levers to change at the level of patients, professionals and organisations.
Study Details
Recently, triple therapy has made it possible to extend access to these modulators to a large proportion of the patient population, with spectacular clinical benefits, provided the patient carries at least one F508del mutation. The hypothesis is that the arrival of CFTRmHEs has considerably altered the way cystic fibrosis is managed, requiring a rethink of how the CRCMs are organised, and a redefinition of the practices and missions of professionals, as well as the patient-professional relationship.
Key Dates
- First listed
- Sep 19, 2024
- Start date
- Sep 1, 2023
- Status verified
- Sep 2024
- Primary completion
- Dec 31, 2026
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 5,000 participants (estimated)
Arms
- Arm: Patients from the 47 CF French centerNational registry indicator study = 7513 patients in total, including 5000 eligible for highly effective CFTRm, for the study of pathways at national level, for which clinical and healthcare consumption data are available in the national registry linked to the SNDS
- Arm: Healthcare professionelsCase study: 8 to 10 CRCMs, 7 to 8 professionals and 7 to 8 patients per CRCM, i.e. 56 to 80 professionals, 200 to 400 patients DELPHI: panel of 80 professionals and patients/parents
Primary Outcome Measure
Obtaining a national consensus on a proposal for a new organisation of the cystic fibrosis care pathway, including the CRCMs and the liberal network [ Time Frame: The outcome measure will be measured at the twelfth month of the survey. ]
Central Contacts
- Philippe REIX, Professor04 27 85 50 42
- Julie HAESEBAERT, Professor04 72 11 57 05
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Natural History of BronchiectasisRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Beta-cell Response to Incretin Hormones in Cystic FibrosisRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Genetics of Insulin and Incretins in Cystic FibrosisRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania